NasdaqCM:CYRX

Stock Analysis Report

Executive Summary

Cryoport, Inc. provides temperature controlled logistics solutions to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Cryoport's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CYRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

10.9%

CYRX

3.2%

US Medical Equipment

0.7%

US Market


1 Year Return

48.6%

CYRX

19.2%

US Medical Equipment

12.9%

US Market

Return vs Industry: CYRX exceeded the US Medical Equipment industry which returned 19.2% over the past year.

Return vs Market: CYRX exceeded the US Market which returned 12.9% over the past year.


Shareholder returns

CYRXIndustryMarket
7 Day10.9%3.2%0.7%
30 Day3.6%4.0%4.4%
90 Day-36.6%3.3%7.0%
1 Year48.6%48.6%20.2%19.2%15.4%12.9%
3 Year519.9%519.9%86.0%80.3%49.1%39.5%
5 Year175.9%175.9%120.3%96.3%62.7%44.7%

Price Volatility Vs. Market

How volatile is Cryoport's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cryoport undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CYRX ($15.56) is trading below our estimate of fair value ($52.89)

Significantly Below Fair Value: CYRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CYRX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: CYRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYRX is overvalued based on its PB Ratio (5.1x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is Cryoport forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

85.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: CYRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CYRX's is expected to become profitable in the next 3 years.

Revenue vs Market: CYRX's revenue (32.6% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CYRX's revenue (32.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CYRX's Return on Equity is forecast to be low in 3 years time (1.2%).


Next Steps

Past Performance

How has Cryoport performed over the past 5 years?

3.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYRX has a high level of non-cash earnings.

Growing Profit Margin: CYRX's current net profit margins (-64.6%) are lower than last year (-55.4%).


Past Earnings Growth Analysis

Earnings Trend: CYRX is unprofitable, but has reduced losses over the past 5 years at a rate of 3.7% per year.

Accelerating Growth: Unable to compare CYRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYRX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.3%).


Return on Equity

High ROE: CYRX has a negative Return on Equity (-17.8%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cryoport's financial position?


Financial Position Analysis

Short Term Liabilities: CYRX's short term assets ($102.2M) exceeds its short term liabilities ($5.7M)

Long Term Liabilities: CYRX's short term assets (102.2M) exceeds its long term liabilities (19.0M)


Debt to Equity History and Analysis

Debt Level: CYRX's debt to equity ratio (13.4%) is considered satisfactory

Reducing Debt: CYRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: CYRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: CYRX's debt is covered by short term assets (assets are 6.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CYRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cryoport's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CYRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CYRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cryoport's salary, the management and board of directors tenure and is there insider trading?

4.8yrs

Average management tenure


CEO

Jerrell Shelton (74yo)

7yrs

Tenure

US$2,772,401

Compensation

Mr. Jerrell W. Shelton, also known as Jerry, has been the Chief Executive Officer and President of CryoPort, Inc. since November 5, 2012 and has been its Chairman of the Board since October 2015. Mr. Shelt ...


CEO Compensation Analysis

Compensation vs Market: Jerrell's total compensation ($USD2.77M) is above average for companies of similar size in the US market ($USD1.73M).

Compensation vs Earnings: Jerrell's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

4.8yrs

Average Tenure

54yo

Average Age

Experienced Management: CYRX's management team is considered experienced (4.8 years average tenure).


Board Age and Tenure

4.8yrs

Average Tenure

69yo

Average Age

Experienced Board: CYRX's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: CYRX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$46,98414 Nov 19
Jerrell Shelton
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares3,356
Max PriceUS$14.00

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.4%.


Management Team

  • Robert Stefanovich (54yo)

    CFO, Treasurer & Corporate Secretary

    • Tenure: 8.4yrs
    • Compensation: US$832.32k
  • Jerrell Shelton (74yo)

    Chairman

    • Tenure: 7yrs
    • Compensation: US$2.77m
  • Raymond Takahashi

    Executive Officer

    • Tenure: 0yrs
  • David Petreccia

    Executive Officer

    • Tenure: 0yrs
  • Bret Bollinger (52yo)

    Chief Technology Officer

    • Tenure: 2.2yrs
    • Compensation: US$174.52k
  • Mark Sawicki

    Chief Commercial Officer

    • Tenure: 4.8yrs
  • Thomas Heinzen

    Vice President of Corporate Development & Investor Relations

    • Tenure: 0yrs
  • Phil Wilson

    Senior Vice President of Global Operations & Supply Chain

    • Tenure: 0.8yrs

Board Members

  • Richard Berman (76yo)

    Lead Director

    • Tenure: 4yrs
    • Compensation: US$331.46k
  • Bill Taaffe (70yo)

    Member of Commercial Advisory Board

    • Tenure: 6.8yrs
  • Ed Zecchini (58yo)

    Independent Director

    • Tenure: 6.2yrs
    • Compensation: US$301.46k
  • Bob Hariri (60yo)

    Independent Director

    • Tenure: 4.2yrs
    • Compensation: US$310.46k
  • Rick Kriss

    Member of Advisory Board

    • Tenure: 11.8yrs
  • Jerrell Shelton (74yo)

    Chairman

    • Tenure: 7yrs
    • Compensation: US$2.77m
  • Larry O’Toole

    Member of Advisory Board

    • Tenure: 0yrs
  • Ram Mandalam (54yo)

    Independent Director

    • Tenure: 5.4yrs
    • Compensation: US$296.46k
  • Dan Hancock (69yo)

    Independent Director

    • Tenure: 0.8yrs

Company Information

Cryoport, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cryoport, Inc.
  • Ticker: CYRX
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$557.725m
  • Shares outstanding: 35.84m
  • Website: https://www.cryoport.com

Number of Employees


Location

  • Cryoport, Inc.
  • 17305 Daimler Street
  • Irvine
  • California
  • 92614
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2005

Biography

Cryoport, Inc. provides temperature controlled logistics solutions to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a clo ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/16 23:55
End of Day Share Price2019/11/15 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.